Vanda Pharmaceuticals Inc (STU:VM4)
€ 4.62 -0.16 (-3.35%) Market Cap: 272.66 Mil Enterprise Value: -78.12 Mil PE Ratio: 0 PB Ratio: 0.54 GF Score: 79/100

Vanda Pharmaceuticals Inc at JPMorgan Healthcare Conference Transcript

Jan 12, 2023 / 08:00PM GMT
Release Date Price: €7.1 (+2.16%)
Raji Gunasekera

Good afternoon. Thank you very much for being here with us today. My name is Raji Gunasekera. I'm an associate on the health care team at JPMorgan. And today, I'm pleased to introduce Vanda Pharmaceuticals, and we have their CFO, Kevin Moran. Thank you.

Kevin Patrick Moran
Vanda Pharmaceuticals Inc. - Senior VP, CFO & Treasurer

Thanks, Raji, and thanks to the entire JPMorgan team for having us today. Very excited to talk to you about the progress of our company, Vanda Pharmaceuticals, as well as our upcoming milestones.

Turning now to our forward-looking statements. Folks should be aware of these as we review the slides in the presentation today. Beginning with our commercialized products. Vanda has 2 products on the market, HETLIOZ and Fanapt. HETLIOZ capsules are approved in the U.S. for Non-24-Hour Sleep-Wake Disorder and nighttime sleep disturbances in patients with Smith-Magenis Syndrome in adults. Additionally, the capsules are approved in Europe for Non-24-Hour Sleep-Wake Disorder. And in addition to HETLIOZ capsules, the HETLIOZ

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot